We can’t show the full text here under this license.
Highly biocompatible nasal mRNA cancer vaccines using carbon dot-lipidoid carriers
Updated
Abstract
Essence
Carbon dot-lipidoid nanoparticles improved intranasal mRNA vaccine delivery and suppressed tumor growth in a preclinical cancer vaccine platform.
Evidence
This formulation and preclinical platform study compared Cdoid-containing with conventional ionizable lipids including SM-102 across in vitro cytotoxicity, in vivo mRNA expression, immune responses, and tumor growth suppression.
Caveat
The abstract does not identify human testing, and the tumor and delivery results remain platform-level preclinical evidence.
Simplified
Key numbers
6.7
of
Measured during acid-base titrations.
60-fold
Luminescence increase
Measured in vivo following .
significantly higher
Increase in and
Quantified through ELISA assays.
mRNA Technology